Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | phenotype | BEFREE | These results with analysis of vaccine-elicited CD8 + T cells for tumor-specific killing and regulatory cell marker expression, add further support to our premise that CD8+ IL-10 + T cells elicited by D52 tumor-self protein vaccine contribute to the suppression of a memory CTL responses and durable tumor immunity. | 31769704 | 2019 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Our results reveal previously unappreciated cooperative roles for T<sub>reg</sub> cell-derived IL-10 and IL-35 in promoting BLIMP1-dependent exhaustion of CD8<sup>+</sup> TILs that limits effective anti-tumor immunity. | 30936494 | 2019 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Interleukin-10 (IL-10) induces an immunosuppressive microenvironment including M2 macrophages, inhibiting anti-tumor immunity. | 29100307 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Interleukin 10 is a cytokine with controversial roles in CD8<sup>+</sup> T cell-mediated anti-tumor immunity. | 28488547 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Lack of IL-10 allows induction of pro-inflammatory cytokines and hinders anti-tumor immunity, thereby favoring tumor growth. | 25056661 | 2014 | ||||
|
0.070 | AlteredExpression | phenotype | BEFREE | This suggests that intraperitoneally administered Th1-like cells, producing elevated levels of IL-10, may require and/or induce differential levels of distinct systemic TReg subpopulations that influence, in part, long-term tumor immunity and enhanced memory/effector CD4-mediated therapeutic potentials. | 22083345 | 2012 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Together, our results demonstrate an antagonistic effect of IL-10 with respect to GM-CSF-induced DC accumulation and tumor immunity and suggest a new mechanism by which tumors escape immune recognition: namely by preventing APC from obtaining access to tumor Ags. | 9218594 | 1997 |